The FDA's Position on Compounded Oral GLP-1s: What Patients Should Know
The regulatory landscape for compounded GLP-1 medications is shifting. The FDA's enforcement stance has intensified through 2025 and 2026, with warning letters, shortage declarations, and litigation all affecting the compounded GLP-1 market. Here's what patients need to know.
The Shortage Question
503A compounding pharmacies can compound copies of FDA-approved drugs during declared shortages. Semaglutide was on the FDA's drug shortage list for an extended period, which opened the door for widespread compounding. As shortage declarations have been updated, the legal basis for some compounded semaglutide products has narrowed.
Compounded oral semaglutide occupies a particularly complex regulatory position because FDA-approved oral semaglutide (Wegovy/Rybelsus) exists as a reference product, but the compounded versions use entirely different delivery mechanisms. Whether a sublingual drop or gummy is truly a "copy" of an FDA-approved SNAC tablet is an unresolved legal question.
FDA Warning Letters
The FDA has issued warning letters to several telehealth providers and compounding pharmacies regarding GLP-1 marketing practices. These letters have targeted misleading claims about efficacy, false implication of FDA approval, and marketing of compounded products as equivalent to branded medications.
MEDVi is among the providers that have received FDA warning letters. We include them in our comparisons for completeness but flag this status clearly. Patients should research any provider's regulatory history before purchasing.
What This Means for Patients
Compounded oral GLP-1 medications remain legal and available from licensed pharmacies. However, patients should understand that the regulatory environment could change, potentially affecting availability of specific products or providers. The safest approach is to work with providers who have clean regulatory records and to stay informed about FDA enforcement actions in this space.
For patients who want to eliminate regulatory uncertainty entirely, FDA-approved oral options (Wegovy, Foundayo) through providers like Sesame Care offer a compliance-safe pathway.